A phase 3, randomized, double-blind, placebo-controlled, multicenter study of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Abbott Biotherapeutics Corp; PDL BioPharma
Most Recent Events
- 06 Oct 2009 New trial record.